Eurofins Scientific SE
ERFSFOTCHealthcare● Active
$72.60
$-3.39(-4.46%)
Market Cap$12.7B
P/E Ratio—
52W High$86.2
52W Low$63.96
Eurofins Scientific SE (ERFSF) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ERFSF · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.47B | $0.55B | $0.31B | $0.78B | $1.06B |
| Depreciation & Amort. | $0.63B | $0.60B | $0.66B | $0.50B | $0.45B |
| Stock-Based Comp. | $0.00B | $0.14B | $0.14B | $0.14B | $0.13B |
| Change in Working Capital | $0.05B | $0.05B | ($0.03B) | $0.03B | ($0.01B) |
| Net Cash from Operations | $1.29B | $1.32B | $1.02B | $1.14B | $1.51B |
| Investing Activities | |||||
| Capital Expenditure | ($0.76B) | ($0.53B) | ($0.55B) | ($0.66B) | ($0.52B) |
| Purchases of Investments | $0.00B | $0.00B | $0.00B | ($0.00B) | ($0.01B) |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.01B |
| Net Cash from Investing | ($1.09B) | ($0.85B) | ($0.68B) | ($0.86B) | ($1.03B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.94B) | ($0.27B) | ($0.06B) | ($0.02B) | ($0.00B) |
| Dividends Paid | ($0.11B) | ($0.10B) | ($0.23B) | ($0.19B) | ($0.13B) |
| Debt Issued / Repaid | $0.91B | ($0.36B) | $0.55B | $0.38B | ($0.45B) |
| Net Cash from Financing | $0.01B | ($1.09B) | $0.41B | ($0.31B) | ($0.91B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.53B | $0.79B | $0.47B | $0.48B | $0.99B |
| FCF Margin %(computed) | 7.33% | 11.37% | 7.18% | 7.09% | 14.74% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · EUR · B
Explore more Eurofins Scientific SE data
About Eurofins Scientific SE (ERFSF) Cash Flow Statement
Eurofins Scientific SE generated operating cash flow of $1.29B and free cash flow of $0.53B for 2025 — a FCF margin of 7.33%. Capital expenditure was ($0.76B).
Frequently asked questions
ERFSF · 4 questionsEurofins Scientific SE generated free cash flow of $0.53B for 2025, down 32.3% year-over-year.
ERFSF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10